Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I went in this morning for a number of shares. Intent was to sell off some in 30 days to offset gains. Will be interested to see what this does on Monday.
Getting up front payments is good, they are selling some equity. 4 million common shares. It looks like around a dollar US. Someone figure out the math CAN/US. However, warrants may not exercise in December. Be interesting to see. If they don't, really not much dilution. Bad for warrant holders. Interesting to see where this goes when it reopens.
Obviously preparing for distribution.
Great. At this rate, they will be drawing the next version of SPORT in crayon.
The only good thing about these idiots is that they have an outside entity building it. I hope Ximedica is incentivized to get it done quickly. They may not get paid.
What ever came out at Ramses? I recall someone saying they had asked a friend to attend.
Seemingly plausible. There are many of what appears too many coincidences lining up that would lead one to believe that something is in the works. I don't think a buy out at this point. Titan still has to produce and demonstrate that it works in a clinical setting. I be liege they are in a position to partner at this point. Someone large could afford to put their toe in the water.
Oh, if you are looking at my valuations, I base that off of ISRG and a growing market. History shows a 4 to 5 multiple when calculating market caps traditionally. Robotics (ISRG ) is much higher. Analysts look at the market potential and estimated growth along with their projected future quarters; that is the reason market caps are higher.
Not sure what you are asking, I speak fast and write fast. I will assume the question marks regard funding. They need money over the next several months. Either they raise it from warrants or they go elsewhere. Further dilution or borrow. I would say further dillution which would be offset by expiring warrants.
SOmething will have to happen in the Fourth quarter based on their dollars on hand. Some news and investors to catapult this so that warrants are exercised or using the recent shelf financing.
If the latter occurs, I believe very little dilution will take place as the warrants expire. Right now, you have to assume that warrants will exercise and it would be prudent to use those numbers trying to figure out future valuations. If they expire, you have to figure in the shelf financing which would offset the expiring warrants. Either way, I believe that when this thing hits full stride, you are looking at 140-150 million outstanding shares. Using a similar multiple of ISRG (7 or slightly higher) you could plug in a revenue number and multiply.
Example: 200 million x 7 equals 1.4 billion, or about 10 dollars a share.
You can do the rest of the math on your own to figure out possible scenarios.
ISRG does somewhere around 2.3 or 2.5 billion a year. Don't recall exactly.
With a growing market and potentially taking market share, Titan is well positioned to exceed my simple math stated above.
Hope that helps.
I believe mid Dec at @ 1.85 a share. If I recall, another set in the Spring and than another set in the Fall. Pricing??? Around $2 dollars I believe.
yes, i believe so.
510K or PMA depend upon classification.
Example: approval has to do with pre market application, such as an implantable. 510K or clearance has to do with premarket notification. i.e. robotics.
Sorry for the curt response, however, I think we get away from the end goal and discussion. Especially from some posters that like to muddy the waters from other boards supporting inferior comparisons.
Oh, and I do know the meaning.
I get it. It's semantics at this point. We all get what we are saying. After 35 years in the business some things just to continue to come out a certain way. A glass of wine can help induce that response. Clearance, approval, whatever, we get the meaning. Lets focus on the bigger issue and the content.
Titan is going to take off and soon everyone on this board will be happy.
You will see revenue from CE mark in 2016 as you suggested. Therefore you will see a small rise in PPS, however, the revenue will be small as it ramps up. Can we get to above the magic number of $4 a share? Don't know. The big bump will come from the FDA approval and their ability to mass produce and deliver the product. Titan is poised to go North from here. The question is, can they have the funds with warrants or do they continue to dilute or finance themselves out of the gate provided they can get takers?
Titan, in my opinion, is going to be a home run. It may take longer than all of us would like. My concern is the inability and inexperience of this management team. They are outside of their element when it comes to true venture capital / start ups.
I personally believe their technology along with the growing robotic market will catapult them to greater heights.
Take a picture
My IPhone just went to 1.56. I'm sure there is an error. Anyone see any news?
Welcome. We need another milestone to fall I believe before we see any significant moment.
It would be great to see that happen. My fear is that time is against us. If they get there act together and deliver, I like the way you are thinking. $3.00 could trigger that 80 million sitting out there.
Maybe the 5 million in warrants at 1.85 in early December never exercise. they use around ten million of the shelf offering and the same happens to the early (spring) 2016 warrants then the fall 2016 warrants. Grant it the price stays down below 2.00 a share to make that happen. You now have eliminated @ 15 million warrants but have used 30 million of shelf offering. It could happen. My feeling is that there will be a little dilution but not as bad as it appears on the surface.
Any thoughts from anyone?
Shelf offering could be used and perhaps warrants never exercised. At least some or most. End of the day, this thing takes longer and overall outstanding shares will net very close to the same.
I don't disagree. Bottom line, I believe the patents are worth more than where we are, therefore I buy more. I look for the next milestone being met to move this stock. Bertner will not move this stock. I hope Fowler is right that he can get all those warrants exercised. At least most.
This person heard JNJ, Stryker and Medtronic. My opinion, in a market that is growing to 20 Billion in the next few years and the multiple that ISRG is trading, I dream of a plus $40 offer. Probably not; however, upper 20's or low 30's would be fantastic. This is all short term of course. If they go it alone and can execute, it will take longer with the possibility of a larger number.
Any thoughts from you guys?
I picked up a lot more today as a few of you did. I am hearing that some large companies are discussing offers but appear to be discouraged due to what Titan is floating out as a number. My broker has another client that is in the business and passed that along to him. My broker thinks I have a lot of shares and cringes a little when I add. He is starting to come around though and starting to believe that this thing has legs. I can't supply any hard details and am always a little skeptical when I hear these things. I have not and will not pump this stock. Take it for what it is worth. I have been in this for many years; I need to look it up. Maybe 5 years and I have been silently and publicly frustrated as many of you have been. Free markets always produce competitors and winners. I believe Titan is that competitor that will take on ISRG.
Back in the 90's I saw Da Vinci and Amadeus side by de at a conference. Amadeus looked very advanced. I have to say, at the time, I could not determine which was superior. I did however observer a a consistent amount of participants at both. If Amadeus does have some relevance, it will be fun to watch. Sport, I believe has the platform for success within the expanding market.
IP cld be sold. Maybe hold onto it and after SPORT is delivered, pursue resurrecting it. Regardless, it could be an additional component that is attractive to a large acquirer.
Looking on the Titan website, under Company / Partners it mentions that one partner,University of Florida has a physician named Li-Ming Su. He is a World renowned Urologist who will serve as lead investigator working with Titan. He is to evaluate the Amadeus.
Could ISRG's patents start expiring soon and is Titan continuing their work on their multiport system? This truely would match them up against ISRG on all fronts. Could explain the need for a lot of cash.
Thoughts on this anyone?
I totally agree. I have always held our that Hargrove is not a start up guy and his ability to execute in a start up was questionable.
TITXF is playing in the field where the money is. The market screams for a competitor. TRXC is in a pillow fight. Perhaps North Korea would purchase one or two.
Actual or threatened harm can get you to court in front of a judge asking for an injunction.
Given that there is relatively small amount of shares traded verses outstanding, could the stock be manipulated for the very reason of getting friends and family in at a lower cost? Not cool , but not out of question! Regardless, how many shares oustanding at the end?
With around 100K outstanding and 40K in warrants, my belief is that either the price goes to were people will exercise the warrants or they will go another round of financing. If they dilute the stock, short term your price stays down. However, warrants will expire offsetting the new round of financing.Either way, without getting too deep, the overall number of shares will stay reactively similar. I expect the stock to bounce around for the next 6-9 months with upward movement being achieved by milestones accomplished.
This will not sell until they execute. Put some numbers on the board with a forward prediction. If they sell this soon, they admit their inabitly to execute as well as admit they have not all their pieces are n place. Result would be a lessor buyout. Be patient. Nothing is a gift, nor does it come easy. Sit tight and wait.
I'm with you there. I believe any additional dilution that takes place will be a result of expiring warrants. I think 140 million O/S is about where we will end up.
Google has a branch that invests in companies. They don't build. JNJ will buy someone. Will it be Titan or someone else down the road?
Just for fun, I couldn't resist, it won't be surgibot. JNJ buys number 1's or 2's in the market space.
Ditto.
Keep in mind, these patents are worth more than the current stock price, as well as a seemingly finished robot that is soon to be in hospitals for their trials. Along with expanded indications for use, this thing at least is several dollars higher in price. Now lets think that if they could actually execute….
It's a roll of the dice with these guys, but if they can, the sky is the limit. Lastly, I seriously doubt that JNJ could actually build something in a new market segment. If they see a market segment expanding they will invest in it thru acquisitions. Titan fits they mold as well as the timeline for getting into an expanding market.
Thoughts anyone?????
684 K stock options granted to employees, directors, etc. Yahoo finance shows it in more detail.
My prediction, unless there is no earth shattering news, we will be trading in this narrow range until the fall. That would put the next set of warrants at jeopardy. However if the news is good , we should see a bump, which I believe it will settle into the fall.
Question? If warrants expire, would that allow them to issue more warrants to friends and family without diluting shares? Keep in mind, if it is true, they just got a capital infusion.
Correct. I believe final end offer was 1.2 billion. Azin P. put the deal together over there. Very smart and now very rich cookie. JNJ got burned, they bought a house of cards. The stent design was the issue with the trial. Not to go into too much detail, the point is, some large companies are willing to spend big dollars in emerging markets. 1.4 billion for Titan would be $10 a share after all warrants exercised. Very reasonable and very cheap for a competitor to ISRG in a market that will grow exponentially. I believe the end product needs to be seen in a clinical trial performing exceptionally. Will it get bought early? Who knows??? If these guys really have something, no way it sells. Execute for a few years. I predicted early, that this was worth 18-24 a share. If they execute, 20-35 based on time frame.
3-5 years